Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UG HealthcareSGX:8K7 +1.32% EBITDA Margin % is 4.41% as of Dec. 2025, which is 45% below its 10-year median of 8.04. The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, UG Healthcare ranks worse than 57.79% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. UG Healthcare's EBITDA for the
six
months ended in Dec. 2025 was S$3.3 Mil. UG Healthcare's Revenue for the
six
months ended in Dec. 2025 was S$74.7 Mil. Therefore, UG Healthcare's EBITDA margin for the quarter that ended in Dec. 2025 was 4.41%.
UG Healthcare (SGX:8K7) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
UG Healthcare EBITDA Margin % Related Terms
UG Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for UG Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:8K7 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, UG Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UG Healthcare EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, UG Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where UG Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UG Healthcare (SGX:8K7) has a EBITDA Margin % of 4.41% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on UG Healthcare and its competitors. This is 45% below median its historical median of 8.04. According to the industry distribution chart, UG Healthcare ranks #471 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 57.8%.
Is UG Healthcare's EBITDA Margin % too high?
UG Healthcare's current EBITDA Margin % of 4.41% is 45% below median its 10-year median of 8.04. The Medical Devices & Instruments industry median EBITDA Margin % is 7.56. UG Healthcare's value of 4.41% is 41.7% below this industry median. Based on the distribution chart, UG Healthcare ranks #471 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does UG Healthcare's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, UG Healthcare ranks #471 out of 815 companies for EBITDA Margin %. This places UG Healthcare in the lower half of its industry. The industry median EBITDA Margin % is 7.56. UG Healthcare's value of 4.41% is 41.7% below this benchmark. While the company's 10-year median is 8.04 vs. the industry median of 7.56, UG Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.56, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UG Healthcare's current EBITDA Margin % of 4.41% is 41.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on UG Healthcare and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UG Healthcare's current EBITDA Margin % is 4.41%, which is 45% below median its own 10-year median of 8.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UG Healthcare stock overvalued right now?
Based on GuruFocus' analysis, UG Healthcare (SGX:8K7) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.13, compared to a current price of S$0.08 — trading 40.8% below its estimated fair value. The current EBITDA Margin % is 4.41%, which is 45% below median its 10-year median of 8.04 and 41.7% below the Medical Devices & Instruments industry median of 7.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For UG Healthcare (SGX:8K7), the current EBITDA Margin % is 4.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
UG Healthcare Corp Ltd is a rubber gloves manufacturer. The company manufactures and distributes products under the Unigloves brand as well as Original Equipment Manufacturer (OEM). The company's business segments are latex examination gloves, nitrile examination gloves, and other ancillary products. It also offers vinyl gloves, surgical gloves and cleanroom gloves, face masks, and other medical disposables. It has two manufacturing plants located in Seremban, Malaysia. Its gloves are used in medical and healthcare, food and beverage, R&D, Industrials and beauty industry. It has a geographical presence with the majority of the revenue generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:8K7 has been successfully added to your 
